Subscribe
shutterstock_1428367415_pavel_kapysh
Pavel Kapysh / Shutterstock.com
13 May 2021Big PharmaMuireann Bolger

Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver

India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
President Xi supports COVID-19 waiver
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
AIPPI weighs in on COVID waiver
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Americas
AstraZeneca sues Dr Reddy's over breast cancer drug
14 February 2017   AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
President Xi supports COVID-19 waiver
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
AIPPI weighs in on COVID waiver
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Americas
AstraZeneca sues Dr Reddy's over breast cancer drug
14 February 2017   AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

More on this story

Big Pharma
President Xi supports COVID-19 waiver
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
AIPPI weighs in on COVID waiver
17 May 2021   The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Americas
AstraZeneca sues Dr Reddy's over breast cancer drug
14 February 2017   AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court